Printer Friendly

Wyeth acquires an additional stake in Wyeth K.K. Japan.

Wyeth (Madison, NJ) announced the purchase of an additional 10 percent stake in Wyeth K.K. ("WKK") bringing Wyeth's ownership interest in the Wyeth/Takeda Pharmaceutical Company Limited joint venture to 80 percent. Wyeth's purchase was made pursuant to an Equity Transfer Agreement entered into by Wyeth and Takeda in May 2003. Financial details of the equity transfer are confidential. Enbrel and Mylotarg, biological products launched in Japan in 2005, are helping to drive WKK's rapid growth.

"The partnership between Wyeth and Takeda to co-promote Enbrel should help make Japan one of the strongest markets for this important biotech product," says Bernard Poussot, President, Wyeth Pharmaceuticals.

The history of WKK begins in 1953 with Lederle (Japan), Ltd., a 50-50 joint venture between the American Cyanamid Company and the then Takeda Chemical Industries, Ltd. In 1994, American Home Products Corporation, now Wyeth, acquired American Cyanamid making it a joint venture between Wyeth and Takeda.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Wyeth

+1-973-660-5218

www.wyeth.com
COPYRIGHT 2006 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Mar 1, 2006
Words:215
Previous Article:Mannatech enforces its ambrotose patent against nutritional supplements firm.
Next Article:Chromos signs agreement with AppTec to manufacture multiple sclerosis drug.
Topics:


Related Articles
PROFITS OF DRUG-MAKER WYETH INCREASE 50%.
Wyeth and Takeda sign arthritis partnership agreement.
DOV Pharmaceutical reorganizes indiplon license.
Y's Therapeutics initiates Phase II clinical trial to evaluate YSPSL in prevention of delayed graft function.
WYETH/PROGENICS START PHASE 2 TRIAL OF ORAL METHYLNALREXONE.
Wyeth and Nycomed announce court denial of preliminary injunction.
Mochida, Wyeth Enter License Agreement for Novel Pain Treatment.
PHARMACOPEIA EARNS MILESTONE PAYMENT FROM WYETH.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters